Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BGLC BioNexus Gene Lab Corp
- Stocks
- Healthcare
- NASDAQ: BGLC
Price (delayed)
$3.97
Market cap
$7.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.08
Enterprise value
$6.26M
Highlights
The debt has grown by 34% year-on-year but it has declined by 5% since the previous quarter
The net income has contracted by 33% from the previous quarter but it has grown by 20% YoY
BioNexus Gene Lab's equity has decreased by 17% YoY and by 7% QoQ
The revenue has declined by 5% year-on-year and by 2.6% since the previous quarter
Key stats
What are the main financial stats of BGLC
Market
Valuations
Earnings
Shares outstanding
1.8M
Market cap
$7.13M
Enterprise value
$6.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.92
Price to sales (P/S)
0.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.68
Revenue
$9.27M
Gross profit
$1.27M
Operating income
-$4.08M
Net income
-$2.12M
EBIT
-$2.11M
EBITDA
-$1.95M
Free cash flow
-$3.24M
Per share
Balance sheet
Liquidity
EPS
-$1.08
EPS diluted
-$1.08
Free cash flow per share
-$1.8
Book value per share
$4.33
Revenue per share
$5.16
TBVPS
$5.28
Total assets
$9.48M
Total liabilities
$1.71M
Debt
$216,427
Equity
$7.77M
Working capital
$4.98M
Debt to equity
0.03
Current ratio
4.19
Quick ratio
3.38
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-21%
Gross margin
13.7%
Net margin
-22.9%
Operating margin
-44%
Return on assets
-20.1%
Return on equity
-24.2%
Return on invested capital
-28.2%
Return on capital employed
-26.7%
Return on sales
-22.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BGLC stock price
How has the BioNexus Gene Lab stock price performed over time
Intraday
-22%
1 week
-33.05%
1 month
43.73%
1 year
-21.54%
YTD
41.79%
QTD
29.32%
Financial performance
How have BioNexus Gene Lab's revenue and profit performed over time
Revenue
$9.27M
Gross profit
$1.27M
Operating income
-$4.08M
Net income
-$2.12M
Gross margin
13.7%
Net margin
-22.9%
The net margin has declined by 36% since the previous quarter but it has grown by 16% year-on-year
BioNexus Gene Lab's operating margin has decreased by 35% YoY and by 15% QoQ
The net income has contracted by 33% from the previous quarter but it has grown by 20% YoY
The operating income has declined by 28% year-on-year and by 12% since the previous quarter
Price vs fundamentals
How does BGLC's price correlate with its fundamentals
Growth
What is BioNexus Gene Lab's growth rate over time
Valuation
What is BioNexus Gene Lab stock price valuation
P/E
N/A
P/B
0.92
P/S
0.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.68
The EPS has grown by 29% YoY but it has contracted by 20% from the previous quarter
The P/B is 69% higher than the last 4 quarters average of 0.7
BioNexus Gene Lab's equity has decreased by 17% YoY and by 7% QoQ
BGLC's price to sales (P/S) is 41% more than its last 4 quarters average of 0.7
The revenue has declined by 5% year-on-year and by 2.6% since the previous quarter
Efficiency
How efficient is BioNexus Gene Lab business performance
The ROS has contracted by 38% from the previous quarter but it has grown by 15% YoY
The ROA fell by 38% QoQ but it rose by 21% YoY
The return on equity has declined by 38% since the previous quarter but it rose by 21% year-on-year
The return on invested capital has declined by 34% since the previous quarter but it has increased by 32% year-on-year
Dividends
What is BGLC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BGLC.
Financial health
How did BioNexus Gene Lab financials performed over time
BioNexus Gene Lab's total liabilities has decreased by 19% QoQ and by 6% YoY
BGLC's total assets is down by 15% year-on-year and by 9% since the previous quarter
The debt is 97% smaller than the equity
The company's debt to equity has surged by 50% YoY
The debt has grown by 34% year-on-year but it has declined by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.